New treatments for neuropathy in the feet include the Qutenza 8 percent capsaicin patch (FDA-cleared for diabetic peripheral neuropathy in 2020), high-frequency spinal cord stimulation (Senza, SENZA-PDN data), and peripheral nerve stimulation devices. Investigational options in trials include selective sodium channel blockers, NGF-pathway modulators, and mitochondria-supporting agents. These newer options layer on top of — not replace — tight glucose control, FDA-approved oral medications, topical capsaicin and lidocaine, and daily foot care.
Qutenza 8% Capsaicin Patch
Qutenza is a prescription 8 percent capsaicin patch applied in a clinic setting. Unlike OTC capsaicin cream (0.025 to 0.075 percent applied daily), Qutenza is a single high-dose application that provides durable relief.
- Pretreatment: topical lidocaine applied for 60 minutes to reduce application discomfort
- Patch application: 30 to 60 minutes on the affected foot area
- Effect onset: within 1 to 3 days
- Duration: up to 12 weeks of pain reduction
- Reapplication: every 3 months
- FDA indication: postherpetic neuralgia, painful diabetic peripheral neuropathy of the feet
Qutenza is typically done in a pain clinic, neurology clinic, or specialty infusion suite. Insurance coverage is common with prior authorization. Transient burning during application is expected and managed with the lidocaine pretreatment.
Spinal Cord Stimulation (SCS)
| Aspect | Detail |
|---|---|
| How it works | Implanted electrodes deliver mild electrical pulses that modulate pain signaling |
| High-frequency SCS device | Nevro Senza (10 kHz waveform) |
| Trial period | 5- to 7-day external trial before permanent implant |
| Evidence (SENZA-PDN) | 86% of SCS patients with ≥50% pain reduction at 6 months vs 5% with medication alone |
| Durability | Benefit persists at 2 years in extension follow-up |
| Candidacy | Refractory pain after adequate trials of first-line medications |
| Invasiveness | Surgical implantation; reversible (can be removed) |
Peripheral Nerve Stimulation (PNS)
Newer, smaller devices target specific peripheral nerves rather than the spinal cord. Examples include StimRouter (Bioness) and SPRINT PNS (SPR Therapeutics). PNS is less invasive than SCS and sometimes used as a bridge therapy or alternative for patients who prefer a lower-profile device. Evidence base is smaller than SCS but growing.
Investigational Oral Agents
| Class | Mechanism | Status |
|---|---|---|
| NaV1.7 selective blockers | Target sensory nerve sodium channels without CNS effects | Phase 2/3 trials |
| NaV1.8 selective blockers (VX-548, suzetrigine) | Similar approach; some encouraging data in acute pain | Early approval for acute pain, neuropathy trials ongoing |
| NGF-pathway modulators | Target nerve growth factor signaling in pain pathways | Ongoing trials (antibodies, small molecules) |
| Angiotensin II receptor blocker (EMA401) | Novel target for neuropathic pain | Trials suspended; revival uncertain |
| Mitochondria-supporting agents (SOMNIOMIX, AS-1) | Aims at underlying nerve dysfunction, not just pain | Early trials |
| Repurposed agents (memantine, mexiletine) | Small-trial evidence for specific patient groups | Off-label use in specialty practice |
Device-Based Options Outside the Clinic
- Home TENS units: $30 to $150; modest benefit; safe to trial
- Nerve-growth-promoting footbeds (e.g., Rebuilder): marketing-heavy, modest evidence; some patients report improvement
- Transcutaneous magnetic stimulation: research-only for neuropathy; used off-label in some pain clinics
- Infrared / anodyne therapy: earlier enthusiasm has cooled after meta-analyses showed limited benefit
- Percutaneous electrical nerve stimulation (PENS): specialty clinic procedure; variable evidence
Emerging Supplement and Nutrition Options
- Benfotiamine (fat-soluble vitamin B1 derivative): 300 to 600 mg daily; modest evidence in European trials
- Acetyl-L-carnitine: 1 to 3 g daily; supports nerve conduction
- Palmitoylethanolamide (PEA): endocannabinoid-like compound; small trials for neuropathic pain
- Methylcobalamin (active B12): strong evidence when B12 deficient, weaker when replete
- Alpha-lipoic acid: continued first-line supplement option at 600 mg daily
What Is Not Yet Proven
- Stem cell injections for diabetic neuropathy — marketing outpaces evidence
- Platelet-rich plasma (PRP) — limited evidence, costly
- Low-level laser therapy — mixed evidence
- Chiropractic manipulation — no evidence for diabetic neuropathy specifically
- Most over-the-counter “nerve support” supplement stacks marketed online
How to Evaluate a “New Treatment” Offer
- Is it FDA-cleared for diabetic peripheral neuropathy?
- Is there published randomized controlled trial data?
- Is it offered in conventional medical clinics or only at private cash-pay clinics?
- Is insurance coverage available?
- Can your primary care clinician or endocrinologist discuss it?
- Is it a one-time cost or recurring expense?
- Does the treatment coordinator share specific success rates?
“Unique proprietary protocol,” “stem cell breakthrough,” or “patented nerve treatment” language should raise skepticism. Legitimate treatments have published data and are covered by insurance.
Layering Treatments Over the Fundamentals
None of the new options replace:
- A1C under 7 percent (tight glucose control)
- Smoking cessation
- B12 replacement if deficient
- Weight management and regular exercise
- Daily foot inspection and proper footwear
- Annual podiatry visit
- FDA-approved first-line medications (pregabalin, duloxetine, tapentadol ER)
Newer treatments are added when the fundamentals have been optimized and pain or dysfunction still limits daily life. See our broader diabetic neuropathy treatments guide.
Related Reading
See our guides on foot neuropathy, neuropathy creams, and supplements for neuropathy.
The Bottom Line
The most important recent additions to foot neuropathy treatment are the Qutenza 8 percent capsaicin patch (FDA-cleared for diabetic peripheral neuropathy in 2020) and high-frequency spinal cord stimulation. Peripheral nerve stimulation, selective sodium channel blockers, and mitochondria-supporting agents are under active development. Home devices (TENS) and supplements (benfotiamine, acetyl-L-carnitine, PEA) have smaller but real roles. Stem cell and PRP marketing outpaces the evidence. Newer treatments work best layered on top of tight glucose control, B12 replacement, and daily foot care — not as substitutes for those fundamentals.
